| Ytd | 158.88% | |
| 1y | 45.71% |
| Open | 10.11 | Prev Close | 10.18 | Low | 10.11 | High | 10.20 | Mkt Cap | 303.24M |
| Vol | 1.69K | Avg Vol | 72.05K | EPS | -0.19 | P/E | -53.58 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 6.46 | 200-d Avg | 4.58 | 1yr Est | 0.00 |
TTRX News
Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its
Turn Therapeutics, Inc. (NASDAQ:TTRX) on Tuesday said a planned interim analysis of its adaptive Pha
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a br
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expa
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, n
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, l
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the anal
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics Inc. (NASDAQ: TTRX - Get Free Report)'s share price traded up 6% during trading on
Athersys (NASDAQ: ATHX - Get Free Report) and Turn Therapeutics (NASDAQ: TTRX - Get Free Report) are
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology c
Turn Therapeutics (NASDAQ: TTRX - Get Free Report) and Bio-Path (NASDAQ: BPTH - Get Free Report) are
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-sta
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025,
